Thriva

Cover Block

Open sources

Field	Value
Name	Thriva
Tagline	Provides at-home finger-prick blood testing, laboratory analysis, and digital health insights for proactive health monitoring [startups.co.uk, 2018] [Forbes, August 2019]
Headquarters	London, UK [TechCrunch, June 2016]
Founded	2015 [TechCrunch, June 2016]
Stage	Series A [Forbes, August 2019] [TechCrunch, May 2020]
Business model	Direct-to-Consumer (DTC) [startups.co.uk, 2018]
Industry	Healthtech [Forbes, August 2019]
Technology type	Software (Non-AI) [startups.co.uk, 2018] [thriva.co]
Geography	Western Europe [TechCrunch, June 2016]
Growth profile	Venture Scale [TechCrunch, May 2020]
Founding team	Hamish Grierson, Eliot Brooks, Tom Livesey [TechCrunch, May 2020] [Business Insider, March 2020]
Funding label	$10M+ [TechCrunch, May 2020] [welcometothejungle.com]
Total disclosed	~$15,700,000 [welcometothejungle.com]

Links

Open sources

• Website: https://thriva.co/

What an Investor Needs First

PUBLIC Thriva is a London healthtech company building at-home finger-prick blood testing with lab analysis and digital follow-up, and it merits attention because it has shown multi-year consumer demand in a category where convenience, clinical trust, and repeat engagement all matter [startups.co.uk, 2018] [Forbes, March 2025]. Founded in 2015, the company emerged from a simple consumer-health premise: routine biomarker testing could move out of clinics for many use cases, with early coverage framing the service around proactive monitoring rather than episodic care [TechCrunch, June 2016] [Forbes, August 2019].

The product flow has been consistent across public reporting: users collect a sample at home, send it for laboratory testing, and receive results through an online dashboard, with early reporting citing turnaround times of roughly 48 hours [startups.co.uk, 2018]. That model appears to differentiate less on novel assay science than on packaging, interpretation, and a consumer-friendly monitoring experience, including tests spanning markers such as thyroid function and iron levels [Forbes] [Business Insider, March 2020].

The founding team brings a mix of fintech and product experience rather than traditional diagnostics pedigrees, which is notable but not disqualifying for a service layer business. Public sources identify Hamish Grierson as co-founder and CEO, with prior experience at Travelex and as an early employee at Tandem, while Eliot Brooks and Tom Livesey are repeatedly cited as co-founders, with Livesey serving as CTO [Crunchbase] [TechCrunch, June 2016] [TechCrunch, May 2020] [Terra API, March 2024].

On financing, Thriva has disclosed a 2017 seed round of $1.9 million, a 2019 Series A of $7.3 million, and a 2020 Series A extension of $5.0 million led by Target Global, implying roughly $14.2 million across those reported rounds [TechCrunch, June 2017] [Forbes, August 2019] [TechCrunch, May 2020]. The business model is primarily direct-to-consumer, with evidence of subscription-style monitoring in early coverage and some later partner distribution signals, but the public record still centers on the consumer proposition rather than a fully documented enterprise pivot [TechCrunch, June 2016] [startups.co.uk, 2018] [LinkedIn].

What matters over the next 12 to 18 months is whether Thriva can translate category familiarity into broader, more durable usage without losing clinical credibility or margin discipline. Public traction points are encouraging, from 20,000 subscribers in 2018 to more than 650,000 tests performed by March 2025, but investors should watch for clearer evidence on repeat purchase behavior, partner-channel contribution, and how far the company can expand beyond wellness-oriented testing into higher-value longitudinal care workflows [startups.co.uk, 2018] [Forbes, March 2025].

Partially corroborated -- This section relies on a mix of independent reporting and company-adjacent sources, with strongest support from TechCrunch, Forbes, Startups.co.uk, Crunchbase, and Terra API.

Taxonomy Snapshot

Axis	Value
Stage	Series A
Business Model	Direct-to-Consumer (DTC)
Industry / Vertical	Healthtech
Technology Type	Software (Non-AI)
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	$10M+ (total disclosed ~$15,700,000)

Inside the Company

Open sources

Thriva began in London in 2015, building around a simple consumer proposition that was still relatively uncommon in UK healthtech at the time: collect a finger-prick blood sample at home, send it to a lab, and review the results digitally rather than starting with an in-person appointment [thriva.co] [Crunchbase]. Public company materials describe the service as at-home blood testing paired with science-backed next steps, while Crunchbase identifies Hamish Grierson as CEO and co-founder [thriva.co] [Crunchbase].

The founding team appears consistently across public profiles as Hamish Grierson, Eliot Brooks, and Tom Livesey, with Livesey serving as CTO according to later profile material [Crunchbase] [TechCrunch, May 2020]. The company website presents Thriva today as an ongoing health monitoring platform with 75+ health markers and annual membership options, which suggests the business has evolved from an early single-test convenience pitch toward a repeat-use monitoring model [thriva.co].

Chronology is clearer on foundation than on corporate form. Crunchbase lists the company as founded in 2015 and headquartered in London, UK, and the current website supports the same operating focus and geography [Crunchbase] [thriva.co]. No state filing or public legal-entity record was included in the source set for this section, so the public record here is strongest on founding date, location, and product direction rather than formal incorporation detail [Crunchbase] [thriva.co].

Verified against public records -- Confirmed by Crunchbase and company website.

Under the Hood

MIXED Thriva’s product is straightforward in concept and more operationally demanding in practice: customers collect a finger-prick blood sample at home, mail it for laboratory analysis, and receive results through a digital interface designed for ongoing health monitoring [startups.co.uk, 2018]. Public reporting describes the service as covering biomarkers such as thyroid function and iron levels, with results historically returned within 48 hours, while later coverage frames the broader use case as giving consumers access to blood data without an initial in-person clinical appointment [startups.co.uk, 2018] [Forbes]. Business Insider separately described the kits as supporting checks from cholesterol to liver function, which is directionally consistent with Thriva’s consumer positioning around routine biomarker tracking rather than acute diagnosis [Business Insider, March 2020].

Website and company-originated materials add more detail, but the evidence standard is weaker and should be read that way. Thriva says its app or dashboard visualizes health data, that every test is reviewed by a Thriva doctor and explained in plain English, and that the service now spans 75-plus health markers, alongside women’s health packages and white-label testing for partners [Thriva]. Those claims fit the company’s long-running emphasis on proactive monitoring, and external reporting does corroborate adjacent use cases such as COVID-19 home antibody testing with the UK government, but the fuller feature set rests primarily on company-controlled sources rather than independent product documentation [Forbes] [Thriva].

There is also some evidence that the product surface has moved beyond pure consumer self-serve testing into channel partnerships. Public references point to workplace benefits distribution through Heka, an in-clinic testing partnership with Superdrug, and a collaboration with Combe Grove, each suggesting that Thriva can package its testing workflow for third-party programs as well as direct users [LinkedIn] [thembsgroup.co.uk] [leadiq.com]. What remains less clear from public materials is the underlying technical architecture, lab partner stack, and the extent to which software differentiation sits in user experience, clinical interpretation, or partner enablement, because none of those layers is described in a verified technical demo or detailed engineering source.

Claim stands unchecked -- This section combines independent press coverage with material claims that rely on Thriva’s own website and company-originated descriptions.

Market Research

Open sources This market matters now because Thriva sits at the intersection of consumer preventative health, home diagnostics, and digitally delivered care, three categories that have attracted sustained attention as patients look for lower-friction ways to monitor health outside the clinic [TechCrunch, June 2016] [Forbes, August 2019].

The evidence base here is narrower than investors might like. No cited third-party market report in the source set gives a clean TAM, SAM, or SOM for at-home biomarker testing specifically, so any sizing discussion has to stay qualitative rather than synthetic. What is supported is the market shape: Thriva was described early as making routine blood testing more convenient through home sampling and a recurring monitoring model [TechCrunch, June 2016], and later coverage continued to frame the product around proactive access to biomarker data without an initial in-person appointment [Forbes, August 2019]. That places the company in an analogous market spanning direct-to-consumer diagnostics, preventive health subscriptions, and digital self-management tools, rather than in a narrow lab-services bucket alone.

Demand signals in the public record point to real consumer pull, even if they do not establish the full addressable market. Startups.co.uk reported 20,000 subscribers across the UK by 2018 [startups.co.uk, 2018]. Forbes later reported that more than 100,000 people across the UK had used Thriva to manage their health by August 2019 [Forbes, August 2019], while TechCrunch said the company was growing 100% year on year as of May 2020 [TechCrunch, May 2020]. Those figures are company traction datapoints, not market-size estimates, but they do suggest that a segment of consumers is willing to pay for repeated testing and interpretation outside the traditional primary-care pathway.

A second tailwind is category normalization through adjacent use cases. Thriva's COVID-era work on home antibody testing with the UK government, as reported by Forbes, matters less as a durable revenue indicator than as evidence that home sample collection and remote result delivery became more legible to mainstream users and institutions during the pandemic [Forbes]. The company has also widened its surface area over time, according to public sources, into workplace benefits through Heka, in-clinic testing through a two-year partnership with Superdrug, and partner-facing white-label offerings on its website [LinkedIn] [thembsgroup.co.uk] [Thriva]. Read conservatively, that points to adjacency beyond pure DTC, with substitutes and complements that include employer health benefits, retail health screening, and clinic-based testing rather than only consumer wellness subscriptions.

Regulation and healthcare system structure cut both ways. The attractive part of the thesis is that blood testing is a familiar clinical modality, and Thriva's model keeps the lab component in the loop rather than asking consumers to interpret raw data alone [startups.co.uk, 2018] [Forbes, August 2019]. The constraint is that healthcare remains more regulated and trust-sensitive than ordinary consumer software. Public materials emphasize doctor review and clinical explanation, but those specific claims are company-sourced and should be treated as such until independently corroborated [Thriva]. For the market overall, that means adoption may benefit from rising consumer interest in prevention, while scaling still depends on clinical governance, regulator comfort, and partner trust.

Cited market-shape signal	Figure	What it likely indicates
UK subscribers by 2018	20,000	Early repeat-use demand for at-home testing [startups.co.uk, 2018]
People served by August 2019	100,000+	Broader consumer uptake beyond an initial niche [Forbes, August 2019]
Growth rate as of May 2020	100% year on year	Strong category momentum during increased interest in remote health access [TechCrunch, May 2020]
Tests performed by March 2025	650,000+	Evidence of sustained use over time, though not a direct market-size proxy [Forbes, March 2025]

The table does not size the market, but it does show a pattern that matters more at this stage: repeated public evidence that home blood testing moved from an early-adopter product toward a more legible consumer health category. The open question is less whether demand exists, and more how large the durable, regulated, repeat-purchase segment proves to be.

Partially corroborated -- Section relies on credible public reporting from TechCrunch, Forbes, and Startups.co.uk, but no named third-party market report in the source set provides a directly corroborated TAM, SAM, or SOM for at-home biomarker testing.

Competition and Substitutes

MIXED Thriva appears to sit between traditional diagnostics pathways and newer consumer health interfaces, with its differentiation resting less on discovery science and more on convenience, repeat engagement, and a consumer-facing interpretation layer around routine blood testing [startups.co.uk, 2018] [Forbes, August 2019] [Thriva].

The competitive map is clearest when broken into substitutes rather than direct named peers, because the source set does not identify a public list of head-to-head startup competitors. On one side sit incumbents: GP-led testing, hospital or clinic phlebotomy, and retail health channels that still require an in-person step. Forbes described Thriva's core proposition as giving consumers access to blood data without an initial clinical appointment, and Startups.co.uk's early reporting framed the product around home collection, lab analysis, and a digital dashboard with turnaround that was typically 48 hours at that stage [Forbes, August 2019] [startups.co.uk, 2018]. That places Thriva in direct competition with conventional care pathways on convenience and user control, even if the underlying laboratory work remains part of the regulated diagnostics stack rather than a new testing modality.

A second competitive set comes from adjacent consumer health products that compete for the same budget and attention rather than for the same workflow. Thriva's website presents "75+ health markers," recurring testing, and science-backed follow-up through an app experience, while Business Insider described the offer in 2020 as at-home kits spanning markers from cholesterol to liver function [Thriva] [Business Insider, March 2020]. In practice, that means wearables, wellness memberships, employer health benefits, and broad preventive-health subscriptions are all substitutes at the demand layer, even when they do not sell the same blood test. The Heka workplace partnership and the reported Superdrug in-clinic rollout suggest the company has already moved beyond a pure direct-to-consumer lane and is contesting employer and retail-distribution surfaces as well [LinkedIn] [thembsgroup.co.uk].

Where Thriva has a real edge today, based on public evidence, is distribution fit for a consumer who wants frequent biomarker checks without entering the healthcare system first. By 2018 the company had 20,000 subscribers in the UK, and Forbes reported more than 100,000 people using its kits by August 2019, before TechCrunch reported 100 percent year-on-year growth and a 50-person team in May 2020 [startups.co.uk, 2018] [Forbes, August 2019] [TechCrunch, May 2020]. Those figures point to a working acquisition and repeat-use model. The edge looks somewhat durable in brand and workflow familiarity, and somewhat perishable in product mechanics, because home sampling, lab processing, and app-based result delivery are features that larger healthcare or retail players can imitate if they control stronger channels or lower-cost customer acquisition [startups.co.uk, 2018] [Thriva].

The main exposure is channel power. A retailer, insurer, national pharmacy chain, or clinic network with existing footfall can offer similar testing access and may own trust, prescribing relationships, or reimbursement pathways that Thriva does not visibly control in the public record. The two-year Superdrug partnership cuts both ways: it expands reach, but it also underlines that some distribution may depend on external platforms rather than wholly owned demand [thembsgroup.co.uk]. Over the next 18 months, the most plausible competitive scenario is that retail-health and employer-benefit channels matter more than stand-alone consumer acquisition. Superdrug is the clearest winner if in-clinic plus at-home hybrid testing proves to be the preferred route for mainstream users, because it already has the physical network named in the sources [thembsgroup.co.uk]. Thriva is the likely loser if customer acquisition shifts decisively toward players that own offline traffic and reimbursement-adjacent trust, unless its partner-led and employer-led distribution scales faster than the public evidence currently shows [LinkedIn] [thembsgroup.co.uk].

Partially corroborated -- This section relies on two or more public sources for Thriva's product position and growth history, but the absence of named startup competitors in the source set means parts of the competitive map are analytical interpretation built from public company, media, and partner evidence rather than direct head-to-head reporting.

Opportunity

PUBLIC The prize here is not another consumer wellness brand, but a scaled diagnostics and monitoring layer that sits between routine blood testing and everyday health decisions for a large share of UK consumers and employer channels.

The headline opportunity is straightforward. If Thriva can turn episodic at-home testing into recurring health monitoring, it could become a durable platform for biomarker-led preventive care outside the clinic, first in direct-to-consumer and then through partner distribution. That is not a purely aspirational leap from a small base. Public reporting shows the company had 20,000 subscribers by 2018 [startups.co.uk, 2018], more than 100,000 people using its kits by August 2019 [Forbes, August 2019], and more than 650,000 tests performed by March 2025 [Forbes]. The product shape also supports that path: home sample collection, lab analysis, and results delivered digitally were established early [startups.co.uk, 2018], while later public evidence points to broader surfaces including workplace benefits, in-clinic partnerships, and white-label distribution [LinkedIn, retrieved 2026] [thembsgroup.co.uk, retrieved 2026] [Thriva].

The more ambitious read is that Thriva does not need to win all of consumer diagnostics to matter. It needs to become a trusted repeat interface for a narrower but valuable set of use cases: cholesterol, liver function, thyroid, iron, and hormone-related monitoring, where users benefit from longitudinal testing rather than a one-off result [Business Insider, March 2020] [Forbes] [Thriva]. The evidence so far suggests the company has already crossed from novelty into repeatable demand, with 100% year-on-year growth reported in May 2020 and a team of 50 at that point [TechCrunch, May 2020].

Scenario	What happens	Catalyst	Why it's plausible
Consumer monitoring default	Thriva becomes the UK reference brand for repeat at-home biomarker tracking, with members testing multiple times per year and using the app as the ongoing record of results and next steps.	Continued product expansion across 75+ markers and doctor-reviewed interpretation keeps the product useful beyond a single kit purchase [Thriva].	The company had 20,000 subscribers by 2018 and over 100,000 people using its kits by 2019, which indicates early repeatable consumer demand rather than one-off press attention [startups.co.uk, 2018] [Forbes, August 2019].
Employer and partner channel expansion	Thriva grows from DTC into a broader benefits and service layer sold through employers, clinics, and branded partners.	Partnerships such as Heka for workplace benefits and Superdrug for in-clinic testing widen distribution without requiring Thriva to acquire every user directly [LinkedIn, retrieved 2026] [thembsgroup.co.uk, retrieved 2026].	Public sources already show movement beyond pure DTC into workplace and retail-health channels, which can support lower customer acquisition costs and broader testing frequency if execution holds [LinkedIn, retrieved 2026] [thembsgroup.co.uk, retrieved 2026].
Diagnostics infrastructure layer	Thriva's white-label offering becomes the back-end testing and reporting engine for third parties that want at-home diagnostics without building the stack themselves.	White-label productization, plus evidence that the company already handles lab workflows, doctor review, and digital reporting, creates a clearer B2B proposition [Thriva] [startups.co.uk, 2018].	The operating pieces are already visible in public reporting: home collection, laboratory processing, dashboard delivery, and interpretation. White-label distribution would extend that same workflow into new channels [startups.co.uk, 2018] [Thriva].

What compounding looks like is less about classic network effects and more about trust, frequency, and distribution density. A consumer who tests once and receives a usable result within a short turnaround can be converted into a longitudinal user, especially when the product covers recurring concerns such as thyroid, iron, cholesterol, liver function, fertility, or menopause-related markers [startups.co.uk, 2018] [Forbes] [Business Insider, March 2020] [Thriva]. Each repeated test makes the dashboard more valuable because the product shifts from a static lab result to a personal time series.

There is also an operational flywheel visible in the public record. More testing volume can improve brand trust and partner appeal, which in turn supports more channels. Thriva's progression from consumer subscriptions [startups.co.uk, 2018] to broader use by more than 100,000 people [Forbes, August 2019], then to COVID-era government-linked testing work [Forbes], and later to workplace and retail partnerships [LinkedIn, retrieved 2026] [thembsgroup.co.uk, retrieved 2026], suggests at least the outline of that sequence. If partner channels scale, the model becomes less dependent on paid consumer acquisition and more dependent on embedded distribution.

The size of the win is harder to pin down because the source set here does not include a confirmed market-size study or a clean public comparable with directly aligned metrics. Even so, the disclosed funding and operating history imply a company still relatively early in capitalization terms, with roughly $15.7 million total disclosed funding according to one secondary profile and £11 million reported after the 2020 extension [welcometothejungle.com] [TechCrunch, May 2020]. If the "consumer monitoring default" or "partner channel expansion" scenario plays out, the upside case is a company worth several multiples of invested capital because it would own a repeat-use care interface rather than a single-test transaction (scenario, not a forecast). The public evidence supports that upside as plausible, but not yet underwritten by enough disclosed financial data to anchor a tighter valuation range.

Partially corroborated -- Built primarily from Forbes, TechCrunch, Startups.co.uk, and company materials, with several material upside enablers resting on company-reported product breadth and partnership evidence from single public sources.

Sources

Open sources

1. [startups.co.uk, 2018] Thriva | https://startups.co.uk/startups-100/2018/40-thriva/

2. [TechCrunch, June 2016] Thriva: Home blood testing for optimal health and performance | https://techcrunch.com/2016/06/19/thriva/

3. [Forbes, August 2019] Thriva secures $7.3M Series A for proactive healthcare | https://www.forbes.com/sites/jamessomauroo/2019/08/01/thriva-secures-73m-series-a-for-proactive-healthcare/

4. [Crunchbase] Hamish Grierson - CEO & Co-Founder @ Thriva - Crunchbase Person Profile | https://www.crunchbase.com/person/hamish-grierson

5. [TechCrunch, May 2020] Thriva raises £4M from Target in an era when at-home blood testing is more crucial than ever | https://techcrunch.com/2020/05/22/thriva-raises-4m-from-target-in-an-era-when-at-home-blood-testing-is-more-crucial-than-ever/

6. [TechCrunch, June 2017] Thriva raises £1.5M from angels, Seedcamp, 500 and LCIF to scale blood testing | https://techcrunch.com/2017/06/13/thriva-raises-1-5m-from-angels-seedcamp-500-and-lcif-to-scale-blood-testing/

7. [Forbes] Eliot Brooks | https://www.forbes.com/profile/eliot-brooks/

8. [Business Insider, March 2020] This startup lets you test your blood at home with a kit to reveal everything from your cholesterol levels to liver function | https://www.businessinsider.com/thriva-blood-tests-home-kit-health-startup-2020-3

9. [Terra API, March 2024] Thriva CTO Tom Livesey | https://tryterra.co/podcast/thriva-cto-tom-livesey

10. [LinkedIn] Thriva LinkedIn page | https://www.linkedin.com/company/thrivahealth/

11. [thriva.co] Home blood testing for optimal health and performance | https://thriva.co/

12. [welcometothejungle.com] Thriva | https://app.welcometothejungle.com/companies/Thriva

13. [BusinessWire, May 2020] Proactive Health Company Thriva Secures £4m Funding From Pan-European Venture Capital Firm Target Global to Further Establish At-Home Health Service | https://www.businesswire.com/news/home/20200522005478/en/Proactive-Health-Company-Thriva-Secures-%C2%A34m-Funding-From-Pan-European-Venture-Capital-Firm-Target-Global-to-Further-Establish-At-Home-Health-Service

14. [The MBS Group] Thriva partners with Superdrug to roll out in-clinic health testing and personalised reports nationwide | https://www.thembsgroup.co.uk/external/thriva-partners-with-superdrug-to-roll-out-in-clinic-health-testing-and-personalised-reports-nationwide/

15. [LeadIQ] Combe Grove company profile | https://leadiq.com/c/combe-grove/5a1d9dff23000059008de6eb